Ameritas Investment Partners Inc. increased its holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 48.1% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 3,525 shares of the company’s stock after buying an additional 1,145 shares during the period. Ameritas Investment Partners Inc.’s holdings in Syndax Pharmaceuticals were worth $61,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors have also bought and sold shares of SNDX. Nisa Investment Advisors LLC boosted its stake in Syndax Pharmaceuticals by 380.0% during the 2nd quarter. Nisa Investment Advisors LLC now owns 2,400 shares of the company’s stock valued at $41,000 after purchasing an additional 1,900 shares during the period. Royal Bank of Canada boosted its stake in Syndax Pharmaceuticals by 833.6% during the 1st quarter. Royal Bank of Canada now owns 2,530 shares of the company’s stock valued at $57,000 after purchasing an additional 2,259 shares during the period. First Mercantile Trust Co. boosted its stake in Syndax Pharmaceuticals by 97.7% during the 1st quarter. First Mercantile Trust Co. now owns 3,937 shares of the company’s stock valued at $88,000 after purchasing an additional 1,946 shares during the period. Healthcare of Ontario Pension Plan Trust Fund acquired a new position in Syndax Pharmaceuticals during the 1st quarter valued at about $96,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in Syndax Pharmaceuticals during the 1st quarter valued at about $106,000.
NASDAQ SNDX opened at $19.31 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 10.81 and a quick ratio of 10.81. The company’s 50 day simple moving average is $16.11 and its 200 day simple moving average is $18.34. Syndax Pharmaceuticals, Inc. has a 12 month low of $13.02 and a 12 month high of $27.85. The company has a market capitalization of $939.01 million, a P/E ratio of -10.27 and a beta of 1.59.
A number of research firms have commented on SNDX. began coverage on shares of Syndax Pharmaceuticals in a research report on Tuesday, May 25th. They set a “buy” rating and a $24.00 price target on the stock. Citigroup began coverage on shares of Syndax Pharmaceuticals in a research report on Tuesday, May 25th. They set a “buy” rating on the stock. Finally, Zacks Investment Research downgraded shares of Syndax Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, August 14th. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, Syndax Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $27.44.
About Syndax Pharmaceuticals
Syndax Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company, which engages in the development of cancer therapies. Its product candidates include SNDX-5613 and SNDX-6352. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in Waltham, MA.
Further Reading: Is the QQQ ETF safe?
Want to see what other hedge funds are holding SNDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX).
Receive News & Ratings for Syndax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.